Long-Term Outcomes of Endoscopic-assisted vs Conventional Breast-conserving Surgery in Breast Cancer Patients After Neoadjuvant Therapy: a Randomized, Multicenter, Open Label, Non-inferiority Trial

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-75
SponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen University

About this trial

With the title of "Long-Term Outcomes of endoscopic-assisted vs conventional breast-conserving surgery in breast cancer patients after neoadjuvant therapy: a randomized, multicenter, open label, non-inferiority trial", this study targets breast cancer patients after neoadjuvant therapy. A total of 804 eligible patients, after screening with inclusion and exclusion criteria, will be randomly assigned to Endoscopic-assisted breast conserving surgery(E-BCS) or conventional breast conserving surgery (C-BCS) group at a 1:1 ratio using stratified block randomization method, stratified by centers and molecular subtype. The co-primary endpoints are 5-year disease-free survival (5y-DFS) and Breast-Q score at 6 months after surgery. The secondary endpoints are cosmetic outcomes including surgeons' satisfaction with breast and patients' satisfaction with scar, survival outcomes including 5-year overall survival (5y-OS) and 5-year local-recurrence rate (5y-LRR), surgical outcomes including operative time, intraoperative blood loss, incision length and postoperative complications rate. This study aims to confirm the long-term safety and aesthetic outcome of endoscopic-assisted surgery in breast cancer patients after neoadjuvant treatment by comparing it with conventional open breast conserving surgery, and provide clinical evidence for the popularized application of endoscopic breast surgery.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ranging from 18 to 75 years

Pathologically confirmed invasive breast cancer

Receiving preoperative chemotherapy (Each molecular subtype corresponds to unanimous regimen)

cT1-3N0-3M0

Disqualifiers

Diffusely disseminated malignant calcification foci

Not applicable for BCS after neoadjuvant therapy

Pregnancy or breastfeeding

Additional malignancy

Trial design

Design model

Parallel

Treatments tested in this trial

  • Surgery

    Procedure/Surgery

    comparison of 2 surgical procedures

Treatment groups

804 Participants
are divided into 2 treatment groups
Group A: Endoscopic breast-conserving surgery (E-BCS) groupExperimental treatment 1 intervention
Group B: Conventional breast-conserving surgery (C-BCS) groupNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

5-year disease free survival

The proportion of patients remaining after excluding patients with disease recurrence, metastasis or death from the time of surgery to 5-year follow-up

Time frame
From surgery to the end of follow-up at 5 years
2

Patients' satisfaction with breast

The score of Breast-Q scale "Satisfaction with breasts" table 6 months after surgery

Time frame
From surgery to the follow-up at 6 months

Secondary outcomes

1

Surgeons' satisfaction with breast

Surgeons evaluate the cosmetic outcome of breast based on the photos before surgery and after surgery. Four ranks: Excellent (9-10 points), Good (7-8 points), Fair (5-6 points) and Poor (0-4 points) are categorized on a basis of average total score from Ueda scale

Time frame
From surgery to the follow-up at 6 months
2

Patients satisfaction with scar

Scar-Q scale including 3 tables about the surgical scar: appearance, symptom, psychosocial impact with total score of 100 will be used for evaluating patients satisfaction with scar

Time frame
From surgery to the follow-up at 6 months
3

5-year overall survival

The proportion of patients remaining after excluding patients who died from any cause at 5-year follow-up

Time frame
From surgery to the end of follow-up at 5 years
4

5-year local-regional recurrence rate

The proportion of patients with a lump found on breast, axilla, chest wall, skin or scars of surgery ipsilateral to the surgical side through physical examination or imaging, confirmed as the same pathological type as the primary tumor according to biopsy at 5-year follow up

Time frame
From surgery to the end of follow-up at 5 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.